Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

Ted Braich, Frederick R. Ahmann, Harinder S. Garewal, Aurelia Robertone, Sydney E. Salmon

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Fifteen patients with hormone resistant advanced prostate cancer were treated with anthracycline analog 4′-deoxydoxorubicin (Esorubicin). No patient had objective evidence of tumor regression. Six patients (40%) were classified using the National Prostatic Cancer Project criteria as having stable disease after two courses of therapy. Treatment was associated with significant hematologic toxicity with 50% of patients experiencing grade III or IV neutropenia. Clinical cardiac toxicity was not observed. Further trials of 4′ -deoxydoxorubicin do not appear to be warranted in advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)193-196
Number of pages4
JournalInvestigational New Drugs
Issue number2
StatePublished - Jun 1986


  • 4′-deoxydoxorubicin
  • phase II
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer'. Together they form a unique fingerprint.

Cite this